18 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
8
Ending by 2030
Dec 2026
Next term end
13
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2029 · High confidence
Also notable
Ends Sep 2032 · High confidence
Also notable
Ends Feb 2037 · High confidence
Stable pharmaceutical compositions of 5,10-methylene tetrahydrofolate
US 9,180,128
Cited by 20 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2029.
18F-SACCHARIDE-FOLATES
US 10,322,195
Granted 2019. Computed term ends 2032.
Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid
US 10,570,134
A family of 5 related applications built on the 2020 grant. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 18, 2026The maintenance fee for 18F-SACCHARIDE-FOLATES (US 10,322,195) comes due Dec 18, 2026. Unpaid by Jun 21, 2027, it lapses early.
- 2 fees due Jan 2 to 23, 2027 · next Jan 2
- 1 fee due Feb 13, 2027The maintenance fee for 18F-LABELLED Folates (US 10,377,756) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
- 1 fee due May 10, 2027The maintenance fee for Stable pharmaceutical compositions of 5,10-methylene tetrahydrofolate (US 9,180,128) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
- 2 fees due Aug 23 to 25, 2027 · next Aug 23
- 1 fee due Sep 29, 2027The maintenance fee for Folate Conjugates of Albumin-Binding Entities (US 9,295,739) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for 18F-LABELLED Folates (US 9,315,506) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 13 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid | 5 in force | to Feb 2037 |
| 18F-SACCHARIDE-FOLATES | 2 in force | to Sep 2032 |
| 18F-LABELLED Folate/Antifolate Analogues | 1 in force | to Mar 2035 |
| Stable Salt of 5,10-Methylene-(6R)-TETRAHYDROFOLIC Acid | 1 in force | to Feb 2035 |
| Folate Conjugates of Albumin-Binding Entities | 1 in force | to Aug 2032 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,463,666 | Pharmaceutical Composition Comprising Progestogens And/Or Estrogens and 5-Methyl-(6S)-TETRAHYDROFOLATE held by Bayer Intellectual Property GmbH and Merck & Cie In force · High confidence | In force | High confidence | |
| US 8,344,140 | 18F-LABELLED Folates In force · High confidence | In force | High confidence | |
| US 10,377,756 | 18F-LABELLED Folates In force · High confidence | In force | High confidence | |
| US 8,021,529 | Ion Measurement/Calibration Cell In force · High confidence | In force | High confidence | |
| US 9,315,506 | 18F-LABELLED Folates In force · High confidence | In force | High confidence | |
| US 9,180,128 | Stable pharmaceutical compositions of 5,10-methylene tetrahydrofolate In force · High confidence | In force | High confidence | |
| US 10,961,246 | 18F-LABELLED Folates as Pet Radiotracers In force · High confidence | In force | High confidence | |
| US 9,265,746 | Method for cell-specific targeting In force · High confidence | In force | High confidence | |
| US 9,295,739 | Folate Conjugates of Albumin-Binding Entities In force · High confidence | In force | High confidence | |
| US 10,973,936 | 18F-SACCHARIDE-FOLATES In force · High confidence | In force | High confidence |
Also on record, not counted in the 18: 1 patent in force now held by others · 7 patents ended · 1 application pending · 13 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.